## WE CLAIM:

- 1. A method for cell activation, the method comprising:
  - (a) introducing a sperm into a mammalian cell;
  - (b) culturing the cell for a time sufficient for cell activation; and
  - (c) removing the sperm from the cell.
- 2. The method of claim 1, wherein the sperm comprises an intact sperm.
- 3. The method of claim 1, wherein the sperm comprises a sperm head.
- 4. The method of claim 1, wherein the sperm comprises a mammalian sperm.
- 5. The method of claim 4, wherein the mammalian sperm comprises a sperm of a mammal selected from the group consisting of a human, a primate, a bovine, a porcine, an ovine, an equine, a feline, a canine, a caprine, a rabbit, and a rodent.
- 6. The method of claim 5, wherein the mammalian sperm comprises a human sperm.
- 7. The method of claim 1, wherein the sperm is heterologous to said mammalian cell to be activated.
- 8. The method of claim 1, wherein the cell comprises a mammalian cell of a mammal selected from the group consisting of a human, a primate, a bovine, a porcine, an ovine, an equine, a feline, a canine, a caprine, a rabbit, and a rodent.
  - 9. The method of claim 8, wherein the cell comprises a human cell.

- 10. The method of claim 1, wherein the embryo is selected from the group consisting of a naturally occurring embryo, an embryo produced by in vitro fertilization, a nuclear transfer embryo, and a uniparental embryo.
- 11. The method of claim 1, wherein the cell has been treated, either before or after introducing the sperm, to remove or inactivate its endogenous nucleus.
  - 12. The method of claim 1, wherein the culturing is performed in vitro or in vivo.
- 13. The method of claim 12, wherein the culturing is performed in vitro and further comprises incubating the injected cell in a medium containing calcium
- 14. The method of claim 1, further comprising the step of injecting the cell with one or more agents that enhance divalent cation release in the cell.
- 15. The method of claim 14, wherein the agent comprises a calcium ionophore, a protein kinase inhibitor, a phosphatase, or a combination thereof.
- 16. The method of claim 1, wherein the cell comprises an oocyte or an embryo, and further comprising culturing the activated cell to undergo embryonic development.
- 17. The method of claim 1, wherein the sperm is removed from the cell 15, 30, or 60 minutes following injection.
- 18. An embryo produced by the method of claim 16, wherein the embryo comprises 1 cell to about 400 cells.
  - 19. The embryo of claim 18, further comprising a blastocyst.
  - 20. A non-human embryo produced by the method of claim 16.

- 21. The embryo of claim 20, further comprising a blastocyst.
- 22. The method of claim 16, wherein said embryo is non-human, and further comprising implanting the non-human embryo into a female surrogate.
- 23. The method of claim 22, wherein said non-human embryo is allowed to develop into a viable, non-human offspring.
  - 24. A non-human offspring produced by the method of claim 23.
- 25. The method of claim 1, wherein the cell is an oocyte or an embryo, and further comprising induction of persistent calcium oscillations within the oocyte or embryo.
  - 26. An activated mammalian cell produced by the method of claim 1.
  - 27. A method for nuclear transfer cloning comprising:
- (a) introducing a mammalian donor cell, or a nucleus derived therefrom into a mammalian enucleated oocyte of the same species as the donor cell or donor cell nucleus, to thereby form a nuclear transfer unit; and
  - (b) activating the oocyte, wherein the activating comprises:
    - (i) injecting a sperm into the oocyte;
    - (ii) culturing the oocyte for a time sufficient for activation; and
    - (iii) removing the sperm from the oocyte.
- 28. The method of claim 27, wherein the activating is performed prior to, simultaneous with, or subsequent to the introducing a mammalian donor cell.
  - 29. The method of claim 27, wherein the sperm is heterologous to the oocyte.
- 30. The method of claim 27, further comprising culturing the nuclear transfer unit to produce an embryo.

- 31. An embryo produced by the method of claim 30, wherein the embryo comprises 1 cell to about 400 cells.
  - 32. The embryo of claim 31, further comprising a blastocyst.
  - 33. A non-human embryo produced by the method of claim 30.
  - 34. The embryo of claim 33, further comprising a blastocyst.
- 35. The method of claim 30, wherein the embryo comprises a non-human embryo, and further comprising implanting the non-human embryo into a female surrogate
- 36. The method of claim 35, wherein said non-human embryo is allowed to develop into a viable, non-human offspring.
  - 37. The non-human offspring produced by the method of claim 36.
- 38. The method of claim 27, wherein the sperm is removed from the oocyte 15, 30 or 60 minutes following implantation.
  - 39. A method for nuclear transfer cloning comprising:
    - (a) activating a mammalian oocyte, the activating comprising:
      - (i) injecting a sperm into the oocyte;
      - (ii) culturing the oocyte for a time sufficient for activation; and
      - (iii) removing the sperm from the oocyte;
    - (b) enucleating the oocyte; and
- (c) introducing into the activated enucleated oocyte a mammalian donor cell, or a nucleus derived therefrom, wherein the donor cell is of the same species as the oocyte, to thereby form a nuclear transfer unit.

- 40. The method of claim 39, wherein the activating is performed prior to, simultaneous with, or subsequent to the enucleating.
- 41. The method of claim 39, further comprising culturing the nuclear transfer unit to produce an embryo.
- 42. An embryo produced by the method of claim 41, wherein the embryo comprises from about 1 cell to about 400 cells.
  - 43. The embryo of claim 42, further comprising a blastocyst.
  - 44. A non-human embryo produced by the method of claim 41.
  - 45. The embryo of claim 44, further comprising a blastocyst.
- 46. The method of claim 41, wherein the embryo comprises a non-human embryo, and further comprising implanting the non-human embryo into a female surrogate
- 47. The method of claim 46, wherein said non-human embryo is allowed to develop into a viable, non-human offspring.
  - 48. The non-human offspring produced by the method of claim 47.
- 49. The method of claim 39, wherein the sperm is removed 15, 30, or 60 following implantation.
  - 50. A method for in vitro fertilization, the method comprising:
- (a) contacting a mammalian oocyte with a plurality of sperm, whereby the oocyte is fertilized; and
  - (b) activating the oocyte, wherein the activating comprises:
    - (i) injecting a sperm into the oocyte;

- (ii) culturing the oocyte for a time sufficient for activation; and
- (iii) removing the sperm from the oocyte.
- 51. The method of claim 50, wherein the contacting is performed prior to, simultaneous with, or subsequent to the activating.
  - 52. An embryo produced by the method of claim 50.
- 53. The method of claim 50, further comprising implanting the embryo into a female surrogate.
- 54. The method of claim 53, wherein said embryo is allowed to develop into a viable offspring.
  - 55. A non-human offspring produced by the method of claim 54.
- 56. The method of claim 50, wherein the sperm is removed from the oocyte 15, 30 or 60 min following implantation.
- 57. The method of claim 16, wherein said embryo is human, and further comprising implanting the human embryo into a female surrogate.
- 58. The method of claim 22, wherein said human embryo is allowed to develop into a viable human offspring.
- 59. The method of claim 30, wherein the embryo comprises a human embryo, and further comprising implanting the human embryo into a female surrogate.
- 60. The method of claim 59, wherein said human embryo is allowed to develop into a viable human offspring.